Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: A randomised controlled trial

International Journal of Obesity

Volumn 30, Issue 12, 2006, Pages 1729-1736

  Wynne, K ^a   Park, A J ^a   Small, C J ^a   Meeran, K ^a   Ghatei, M A ^a   Frost, G S ^a   Bloom, S R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Activity; Appetite; Energy expenditure; Oxyntomodulin; Proglucagon

Indexed keywords

GHRELIN; GLUCOSE; INSULIN; LIOTHYRONINE; OXYNTOMODULIN; THYROTROPIN; THYROXINE;

ADULT; APPETITE; ARTICLE; BODY MASS; BODY WEIGHT; CALORIMETRY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; DRUG SELF ADMINISTRATION; ENERGY EXPENDITURE; EXERCISE; FEMALE; HEART RATE; HORMONE BLOOD LEVEL; HUMAN; MALE; NAUSEA; OBESITY; PATIENT MONITORING; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANTI-OBESITY AGENTS; BLOOD PRESSURE; BODY MASS INDEX; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENERGY INTAKE; ENERGY METABOLISM; FEMALE; HEART RATE; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; OXYNTOMODULIN; SELF ADMINISTRATION;

EID: 33749339257     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0803344     Document Type: Article

References (32)

1. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 2004; 291: 2847-2850.
2. Ravussin E, Bogardus C. Energy balance and weight regulation: genetics versus environment. Br J Nutr 2000; 83 (Suppl 1): S17-S20.
3. Weinsier RL, Hunter GR, Heini AF, Goran MI, Sell SM. The etiology of obesity: relative contribution of metabolic factors, diet, and physical activity. Am J Med 1998; 105: 145-150.
4. Gura T. Obesity drug pipeline not so fat. Science 2003; 299: 849-852.
5. Ghatei MA, Uttenthal LO, Christofides ND, Bryant MG, Bloom SR. Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract. J Clin Endocrinol Metab 1983; 57: 488-495.
6. Cohen MA, Ellis SM, Le Roux CW, Batterham RL, Park A, Patterson M et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 2003; 88: 4696-4701.
7. Dakin CL, Small CJ, Park AJ, Seth A, Ghatei MA, Bloom SR. Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. Am J Physiol Endocrinol Metab 2002; 283: E1173-E1177.
8. Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M et al. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 2004; 145: 2687-2695.
9. Wynne K, Park AJ, Small CJ, Patterson M, Ellis SM, Murphy KG et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 2005; 54: 2390-2395.
10. Rissanen AM, Heliovaara M, Knekt P, Reunanen A, Aromaa A. Determinants of weight gain and overweight in adult Finns. Eur J Clin Nutr 1991; 45: 419-430.
11. Astrup A, Gotzsche PC, van de WK et al. Meta-analysis of resting metabolic rate in formerly obese subjects. Am J Clin Nutr 1999; 69: 1117-1122.
12. Buscemi S, Verga S, Caimi G, Cerasola G. Low relative resting metabolic rate and body weight gain in adult Caucasian Italians. Int J Obes Relat Metab Disord (London) 2005; 29: 287-291.
13. Weinsier RL, Nagy TR, Hunter GR, Darnell BE, Hensrud DD, Weiss HL. Do adaptive changes in metabolic rate favor weight regain in weight-reduced individuals? An examination of the set-point theory. Am J Clin Nutr 2000; 72: 1088-1094.
14. Wyatt HR, Grunwald GK, Seagle HM, Klem ML, McGuire MT, Wing RR et al. Resting energy expenditure in reduced-obese subjects in the National Weight Control Registry. Am J Clin Nutr 1999; 69: 1189-1193.
15. Zurlo F, Ferraro RT, Fontvielle AM, Rising R, Bogardus C, Ravussin E. Spontaneous physical activity and obesity: cross-sectional and longitudinal studies in Pima Indians. Am J Physiol 1992; 263 (2 Part 1): E296-E300.
16. Hunter GR, Byrne NM. Physical activity and muscle function but not resting energy expenditure impact on weight gain. J Strength Cond Res 2005; 19: 225-230.
17. Levine JA, Eberhardt NL, Jensen MD. Role of nonexercise activity thermogenesis in resistance to fat gain in humans. Science 1999; 283: 212-214.
18. Morgan JF, Reid F, Lacey JH. The SCOFF questionnaire: assessment of a new screening tool for eating disorders. BMJ 1999; 319: 1467-1468.
19. Van Strien T, Rookus MA, Bergers GP, Frijters JE, Defares PB. Life events, emotional eating and change in body mass index. Int J Obes 1986; 10: 29-35.
20. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349: 941-948.
21. Brage S, Brage N, Franks PW, Ekelund U, Wareham NJ. Reliability and validity of the combined heart rate and movement sensor Actiheart. Eur J Clin Nutr 2005; 59: 561-570.
22. Rennie K, Rowsell T, Jebb SA, Holburn D, Wareham NJ. A combined heart rate and movement sensor: proof of concept and preliminary testing study. Eur J Clin Nutr 2000; 54: 409-414.
23. Brage S, Brage N, Franks PW, Ekelund U, Wong MY, Andersen LB et al. Branched equation modeling of simultaneous accelerometry and heart rate monitoring improves estimate of directly measured physical activity energy expenditure. J Appl Physiol 2004; 96: 343-351.
24. English PJ, Ghatei MA, Malik IA, Bloom SR, Wilding JP. Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab 2002; 87: 2984.
25. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987; 2: 1300-1304.
26. Castaneda TR, Jurgens H, Wiedmer P, Pfluger P, Diano S, Horvath TL et al. Obesity and the neuroendocrine control of energy homeostasis: the role of spontaneous locomotor activity. J Nutr 2005; 135: 1314-1319.
27. World Health Organization. Obesity:preventing and managing the global epidemic. World Health Organization: Geneva, 2000. Report No.: 894.
28. Baggio LL, Huang Q, Brown TJ, Drucker DJ. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 2004; 127: 546-558.
29. Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 2001; 25: 781-792.
30. Osaka T, Endo M, Yamakawa M, Inoue S. Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by the lower brainstem and sympathoadrenal system. Peptides 2005; 26: 1623-1631.
31. Shalev A, Holst JJ, Keller U. Effects of glucagon-like peptide 1 (7-36 amide) on whole-body protein metabolism in healthy man. Eur J Clin Invest 1997; 27: 10-16.
32. Wynn V, Abraham RR, Densem JW. Method for estimating rate of fat loss during treatment of obesity by calorie restriction. Lancet 1985; 1: 482-486.